"An ideal drug for NASH would be a drug that targets fat deposition,... has anti-inflammatory and ant-fibrotic properties, and...reduces cardiovascular risk, which is the most frequent cause of mortality in NASH." ...(NIH)

"Currently, the time tested diet and exercise therapy remains the most effective and cost saving intervention for management of NAFLD."...(NIH)

The two drugs ahead in the pipeline are OCA (obiticholic acid),...which is awaiting FDA approval and Saroglitazar, which has been approved in India for use in NASH, although long-term data on fibrosis improvement... are still awaited...(NIH)